8.49

0.65% -0.010

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $8.49, with a volume of 296.75K. It is down -0.65% in the last 24 hours and down -10.63% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Previous Close:

$8.50

Open:

$8.51

24h Volume:

296.75K

Relative Volume:

0.68

Market Cap:

$601.37M

Revenue:

Net Income/Loss:

$-100.70M

P/E Ratio:

-3.8945

EPS:

-2.18

Net Cash Flow:

$-86.54M

1W Performance:

-18.01%

1M Performance:

-10.63%

6M Performance:

-7.81%

1Y Performance:

+23.46%

1-Day Range:

$8.1225

$8.805

1-Week Range:

$8.105

$11.11

52-Week Range:

$6.33

$16.65

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

112

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC	8.49	601.37M	0	-100.70M	-86.54M	-2.18
VRTX	466.78	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	759.96	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.96	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	231.32	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.42	24.08B	3.30B	-501.07M	1.03B	11.54

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

05:29 AM

ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World

Nov 14, 2024

Nov 13, 2024

Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks

Nov 13, 2024

Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com

Nov 13, 2024

Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Nov 13, 2024

FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com

Nov 12, 2024

ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire

Nov 12, 2024

ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World

Nov 08, 2024

Nov 06, 2024

ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024

Nov 04, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Long Term Trading Analysis for (ORIC) - Stock Traders Daily

Nov 03, 2024

Nov 01, 2024

Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN

Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World

Nov 01, 2024

Oct 29, 2024

Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology

Oct 29, 2024

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study - Investing.com

Oct 23, 2024

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire

Oct 23, 2024

Oct 16, 2024

Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex

Oct 16, 2024